NeoGenomics (NEO) Investor Update summary

Product development and technology update

• Updated RaDaR assay has completed feasibility and is moving to design, development, and CLIA validation, targeted for the first half of 2025.

• The new version maintains proprietary bioinformatics and high sensitivity, with modifications to early DNA processing steps.

• Multiple R&D projects are ongoing, with future versions focused on further improving sensitivity and clinical outcomes.

• The platform's bioinformatics remain protected by a portfolio of patents.

Legal and financial status

• Settlement with Natera regarding RaDaR 1.0 is not material to financials and does not impact Adjusted EBITDA guidance or liquidity.

• Natera will no longer assert the '035 patent against RaDaR 1.0 or the updated product; litigation on the '454 patent continues, with a trial expected in the second half of next year.

• Legal expenses and financial guidance for 2024 remain unchanged; long-term revenue guidance excludes clinical RaDaR revenue.

• Confidential terms of the settlement ensure no material impact on bottom line.

Clinical trials and strategy

• Six ongoing clinical trials using RaDaR 1.0 will continue under court-approved carve-outs, ensuring patient care is uninterrupted.

• Clinical trial costs are included in current financial guidance, and the company is focused on building clinical evidence for the new version.

• The company is pursuing partnerships to expand the RaDaR platform and is open to complementary technologies.